Document is current
Any future updates will be listed below
-
Authors
Wainberg, Zev A. https://orcid.org/0000-0002-7142-1246
Link, Jason M. https://orcid.org/0000-0002-6892-0431
Premji, Alykhan
Zheng, Serena https://orcid.org/0000-0003-3666-0513
Srienc, Michael https://orcid.org/0009-0009-0485-4154
Hammons, McKensie
Kim, Shineui E.
Li, Luyi
Liu, Zeyu
Tsvetkova, Olga
Abt, Evan R.
Rosen, Lee
Kim, Stephen
King, Jonathan
Hines, O. Joe
Girgis, Mark
Sadeghi, Saeed
Olevsky, Olga
Wong, Deborah
Yonemoto, Lisa
Siney, Ann Marie
Kelly, Kim
Kivork, Christine
Tseng, Chi-Hong https://orcid.org/0000-0002-2549-6167
Radu, Caius G. https://orcid.org/0000-0002-9338-5397
Dawson, David W.
Donahue, Timothy R. https://orcid.org/0000-0002-1175-2545
-
Funding
Funding for this research was provided by:
Hirshberg Foundation for Pancreatic Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1CA250529)
- License Information
-
More Information
Article History
Received: 19 September 2025
Accepted: 22 January 2026
First Online: 31 January 2026
Competing interests
: Dr. Wainberg is an advisor for Amgen, Alligator, Astra Zeneca, Daiichi, Bayer, BMS, Merck, Ipsen, Gilead, Arcus, Astellas, Lilly, Pfizer, Revolution Medicine. Dr. Wong reports consulting from Merck, RAPT Therapeutics, Coherus Biosciences, Fennec Pharma, Merus and Bicara. Drs. Radu and Donahue report support from Trethera Corporation outside the submitted work. The other authors declare no competing interests.
